Materias dentro de su búsqueda.
Mostrando 2,921 - 2,940 Resultados de 58,773 Para Buscar '"Her"', tiempo de consulta: 0.71s Limitar resultados
  1. 2921
    “…BACKGROUND: Echocardiograms are recommended every 3 months in patients receiving human epidermal growth factor 2 (HER2)-targeted therapy for surveillance of left ventricular ejection fraction (LVEF). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Rationale and design of a cardiac safety study for reduced cardiotoxicity surveillance during HER2-targeted therapy
  2. 2922
    Publicado 1799
    Enlace del recurso
    Online Artículo Texto
    A Table, Shewing the Different Diseases and Casualties Which Occurred on Board His Majesty's Ship, Astræa, from Her Leaving England for the Jamaica Station, in January, 1787, to Her Arrival at Chatham, in June, 1790; Comprehending a Period of Three Years and Six Months
  3. 2923
    “…BACKGROUND: Dual blockade of HER2 promises increased pathological complete response (pCR) rate compared with single blockade in the presence of chemotherapy for HER2-positive (+) primary breast cancer. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Efficacy and safety of trastuzumab, lapatinib, and paclitaxel neoadjuvant treatment with or without prolonged exposure to anti-HER2 therapy, and with or without hormone therapy for HER2-positive primary breast cancer: a randomised, five-arm, multicentre, open-label phase II trial
  4. 2924
    por Spark, Muriel
    Publicado 1985
    Libro
    Emily Brontë : her life and work /
  5. 2925
    por Schneer, Georgette
    Publicado 1994
    Libro
    Movement improvisation : in the words of a teacher and her students /
  6. 2926
    por Bennett, Sophia Elizabeth
    Publicado 2017
    “…Collide Pro Helvetia 2017 Artist Laura Couto Rosado with her scientific partner James Beacham in the CERN workshop…”
    Enlace del recurso
    Collide Pro Helvetia 2017 Artist Laura Couto Rosado with her scientific partner James Beacham in the CERN workshop
  7. 2927
    por Ordan, Julien
    Publicado 2020
    “…Visit by His Excellency Mr Luca Boschi and Her Excellency Ms Mariella Mularoni Captains-Regent Republic of San Marino…”
    Enlace del recurso
    His Excellency Mr Luca Boschi and Her Excellency Ms Mariella Mularoni Captains-Regent Republic of San Marino
  8. 2928
    “…BACKGROUND: Human epidermal growth factor receptor 2 (HER2) is a landmark protein in determining the targeted treatment of breast cancer (BC). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Bioinformatics combined with clinical data to analyze clinical characteristics and prognosis in patients with HER2 low expression breast cancer
  9. 2929
    “…BACKGROUND: We aimed to establish and validate 2 machine learning models using (18)F-flurodeoxyglucose positron emission tomography/computed tomography ((18)F-FDG PET/CT) radiomic features to predict human epidermal growth factor receptor 2 (HER2) expression and prognosis in gastric cancer (GC) patients. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Preoperative (18)F-FDG PET/CT radiomics analysis for predicting HER2 expression and prognosis in gastric cancer
  10. 2930
    “…CONCLUSION: Adding pyrotinib to pembrolizumab and lenvatinib may represent a promising strategy for advanced ICC patients who have high levels of HER2.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Clinical response to adding pyrotinib to pembrolizumab and lenvatinib for HER2-positive advanced intrahepatic cholangiocarcinoma: a case report
  11. 2931
    “…BACKGROUND: We aimed to investigate the prognostic significance of insulin resistance (IR) markers fasting triglyceride-glucose (TyG) index and triglyceride high-density lipoprotein cholesterol (TG/HDL-C) ratio in HER2-positive breast cancer (BC) patients with brain metastasis (BM). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    The Potential Prognostic Marker TyG Index Predicts Time to Brain Metastasis at HER2 Positive Breast Cancer
  12. 2932
    “…In this paper, we present the case of a leptomeningeal carcinomatosis patient who experienced complete remission following therapy targeted at the Her-2 (human epidermal growth factor receptor 2-positive) receptor. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Complete Cerebrospinal Fluid Response to T-DM1 in HER2 Positive Metastatic Breast Cancer: A Case Report
  13. 2933
    “…HER-2/neu-specific T cell immunity has been shown to predict immunologic and clinical responses in PCa patients treated with HER-2/neu peptide vaccines. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Frequencies of an Immunogenic HER-2/neu Epitope of CD8+ T Lymphocytes Predict Favorable Clinical Outcomes in Prostate Cancer
  14. 2934
    “…BACKGROUND: Neoadjuvant therapy has become the standard treatment for early human epidermal growth factor receptor 2 (HER2)-positive breast cancer, with most regimens using a combination of anti-HER2-targeted drugs and chemotherapy. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Neoadjuvant therapy with vs. without anthracyclines for HER2-positive breast cancer: a systematic review and meta-analysis
  15. 2935
    “…BACKGROUND: HER2-low could be found in some patients with triple-negative breast cancer (TNBC). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Clinical and biological heterogeneities in triple-negative breast cancer reveals a non-negligible role of HER2-low
  16. 2936
    “…SIMPLE SUMMARY: Resistance to anti-HER2+ therapy remains the main clinical challenge in the management of the HER2+ breast cancer subtype. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    miR-146a-5p Promotes Angiogenesis and Confers Trastuzumab Resistance in HER2+ Breast Cancer
  17. 2937
    “…HER2-positive gastric cancer (GC) makes up 15–20% of all GC incidences, and targeted therapy with trastuzumab is the standard of treatment. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Exploring potential molecular resistance and clonal evolution in advanced HER2-positive gastric cancer under trastuzumab therapy
  18. 2938
    “…We describe the effect of two Polypurine Reverse Hoogsteen (PPRH) hairpins directed against the ERBB2 gene, which is overexpressed in positive HER-2 breast tumors. The inhibition of their target was analyzed by cell viability and at the mRNA and protein levels. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    In Vitro and In Vivo Effects of the Combination of Polypurine Reverse Hoogsteen Hairpins against HER-2 and Trastuzumab in Breast Cancer Cells
  19. 2939
    “…BACKGROUND: Established mouse models of HER2+ cancer are based on the over-expression of rodent Neu/Erbb2 homologues, which are incompatible with human HER2 (huHER2) targeted therapeutics. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Syngeneic mouse model of human HER2+ metastatic breast cancer for the evaluation of trastuzumab emtansine combined with oncolytic rhabdovirus
  20. 2940
    “…BACKGROUND: Recent studies have investigated the features of breast cancer (BC) with low human epidermal growth factor receptor 2 (HER2) expression or HER2-0 expression. However, the results were inconsistent. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Comparison of the pCR Rate and DFS Among Breast Cancer Patients with Different Hormone Receptor and HER2 Statuses
Herramientas de búsqueda: RSS